New antifungal drug APX001 passes first safety check in humans
NCT ID NCT02956499
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested the safety and tolerability of a new antifungal drug called APX001 in 200 healthy volunteers. Participants received either single or multiple doses of the drug or a placebo. The study focused on side effects and how the drug moves through the body, not on treating infections. It is a necessary first step before testing the drug in patients with fungal infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APX001
What this could lead to
If successful, this could lead to a new treatment option for serious fungal infections, especially for patients who don't respond to current medicines.
What could go wrong
This is a very early Phase 1 trial in healthy people, not patients. It only checks safety and dosing, not whether the drug actually works against infections. Many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PRA Health Sciences
Groningen, 9728 NZ, Netherlands
-
PRA Health Sciences
Groningen, Netherlands